Hospital Universitario De La Ribera

Alzira 25 trials 6 recruiting

25 Registered trials

6 Currently recruiting

Organisation

Hospital Universitario De La Ribera

Location

Alzira, Spain

Identifier

ORG-100042272

Address

Carretera Corbera Km 1, 46600, Spain

Departments

#3435: Medicina Interna
Endocrinology
Endocrinology and Nutrition
ES30012:Hematologia
Geriatría
Internal Medicine Service
Medical Oncology
N/A
Neurology
Neurophysiology and sleep disorders unit
Oncology Department
Pneumology
Pneumology Department
Servicio de Endocrinologia
Sleep Unit
Urology

Clinical trials at this site (25)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending

2025-523911-13-00 Narcolepsy Type 1 5
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 Pending

2025-523912-35-00 Narcolepsy Type 2 5
A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with… Recruiting

2024-516616-24-00 Acromegaly 5 2025-07-23
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
eValuating the efficacy and safety of InitiatinG depemokImab earLy therApy iN COPD with Type 2 inflammation (VIGILANT) Recruiting

2025-521108-23-00 Chronic Obstructive Pulmonary Disease 5 2026-05-19
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN THE CORRECTION OF DEFICIT IN SUBJECTS WI… Ended

2024-514528-17-00 Severe vitamin D deficiency 6 2025-09-15
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Ended

2024-515162-13-00 Eosinophilic Asthma 5 2025-04-29
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell… Ended

2024-513539-25-00 Type 2 Diabetes Mellitus 4 2024-11-22
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended

2023-508462-15-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 10 2023-04-27
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended

2024-510967-41-00 Metastatic colorectal cancer 5 2018-09-21
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2024-511998-30-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-10-18
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2023-508465-32-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-09-03
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Sleep disturbances associated with menopause 4 2024-03-14
A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended

2022-502313-28-00 Diabetic Peripheral Neuropathic Pain 4 2023-12-14
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Cardiovascular Disease 5 2023-09-05
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14